NCT01675284
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine prevention 1 completed NCT01335347
Safety Study of an Oral Vaccine to Prevent Avian Influenza No drug interventions prevention 1 completed NCT01006798
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 No drug interventions prevention 1 completed NCT01052402
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents No drug interventions prevention 1 / 2 completed NCT03745274
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults No drug interventions prevention 1 completed NCT03038776
Recombinant H7 Hemagglutinin Influenza Vaccine Trial No drug interventions prevention 1 completed NCT00561184
Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine No drug interventions prevention 2 completed NCT02921997
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses prevention 2 completed NCT02251288
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine No drug interventions prevention 1 completed NCT02612909
A Safety and Immunogenicity Study of IVACFLU-A/H5N1 No drug interventions prevention 2 / 3 completed NCT03318315
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 No drug interventions prevention 2 completed NCT01150552
Studies of Avian Influenza Transmission to Humans in Egypt No drug interventions Not Available Not Available completed NCT02295813
Safety and Pharmacokinetics Study of FBF001 treatment 1 completed NCT02624219
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults prevention 1 completed NCT02839330
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age No drug interventions prevention 3 completed NCT00481065
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects No drug interventions prevention 2 completed NCT03312231
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly No drug interventions prevention 2 completed NCT01698060
Immunogenicity of ND1.1 by Delivery Directly to the Ileum No drug interventions prevention 1 completed NCT01107262
Avian Influenza Studies In Lebanon No drug interventions Not Available Not Available completed NCT01897701
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 No drug interventions prevention 1 completed NCT03014310
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology prevention 1 completed NCT00298233
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza treatment 2 completed NCT02213354
H7N9 Mix and Match With MF59 in Healthy Elderly Persons No drug interventions prevention 2 completed NCT03589807
2013/2017 H7N9 Prime-Boost Interval No drug interventions prevention 2 completed NCT01511419
Safety Trial of Live Attenuated Influenza (H7N3) Vaccine No drug interventions prevention 1 completed NCT03738241
2017 A/H7N9 IIV Revaccination No drug interventions prevention 2 completed NCT02229357
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine No drug interventions prevention 2 completed NCT03682120
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza No drug interventions prevention 2 completed NCT03472976
H5N1 With or Without Topical Aldara in Healthy Adults prevention 1 completed NCT00895544
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults No drug interventions prevention 1 / 2 completed NCT02107807
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine No drug interventions prevention 3 completed NCT00383071
Development of Immune Globulin Treatment for Avian Flu No drug interventions other 2 terminated